Researchers have been battling to find the cure for cancer since we began to understand what cancer really was. A cure is the ultimate goal, but most medical professionals and patients would be ecstatic even hearing about new treatments. Current cancer treatments often come rife with side effects so severe that many choose to forgo them altogether. Stopping the growth of malicious cancer cells is the main goal of treatment, and removing them altogether is even better. The problem is, this kind of treatment almost always causes damage to surrounding healthy cells.
A treatment that changes cancerous cells into healthy, supportive cells sounds ideal. Transforming malignant cells into antibodies that would attack remaining cancer cells sounds too good to be true. Thanks to a groundbreaking study by scientists at The Scripps Research Institute (TSRI), this new, powerful form of cancer therapy could really be on the horizon.
An Accidental Discovery
The laboratory team was working on therapies for certain immune cell or blood factor deficiencies when they noticed some unusual effects of antibodies on marrow cells. They had been searching for antibodies that activate growth-factor receptors on immature bone marrow cells, meaning the antibodies would be able to induce these cells to mature into specific blood cell types.
After successfully identifying a number of antibodies that activated the bone marrow cell-receptors this way, the researchers noticed that some of the antibodies were having unexpected effects on the cells. Some of them were maturing into cells that were radically different from what had been expected, such as neural cells. This got the team thinking, could this method be used to convert cancerous marrow cells (leukemia cells) into non-cancerous cells?
Transformation
In the new study, Richard A. Lerner, institute professor and the Lita Annenberg Hazen professor of Immunochemistry at TSRI and senior investigator, teamed up with colleagues, including first author Kyungmoo Yea, an assistant professor of cellular and molecular biology at TSRI. They decided to test 20 of the recently discovered receptor-activating antibodies on acute myeloid leukemia cells taken from human patients. One of the antibodies ended up having an incredible impact on the leukemia cells.
Most acute myeloid leukemia cells have the thrombopoietin (TPO) receptor, a receptor the winning antibody selectively and potently activated in marrow cells. When the antibody was applied to healthy marrow cells, the cells matured into blood-platelet-producing cells (megakaryocytes). When applied to the acute myeloid leukemia cells, though, the antibody caused them to mature into dendritic cells, which are key support cells in the body’s immune system.
This alone would have been a success — the researchers had effectively transformed cancerous cells into non-cancerous, helpful immune system cells. The team pushed further, though, and found that with longer exposures to the antibodies and other regulated conditions, the dendritic cells matured even more. The final product was a group of cells that very closely resembled natural killer (NK) cells. One of the body’s rapid immune defenses, NK cells are capable of rapidly attacking potentially dangerous pathogens and tumors even if they don’t contain the biomarkers normally identified by other immune cells.
“That antibody could have turned those acute myeloid leukemia cells into a lot of other cell types, but somehow we were lucky enough to get NK cells,” Lerner said in a press release.
‘Fratricide’
These induced NK cells possessed a few unique characteristics, observed by the team through electron microscopy. The cells possessed extending tendrils that had made their way through the outer membranes of closeby leukemia cells — the kind of cells they would still be, had they not been exposed to the antibody. In lab tests, the NK cells betrayed their former brethren at an impressive pace: a “modest” number of NK cells took out about 15 percent of the surrounding leukemic cell population in only 24 hours.
An interesting detail noted by the researchers is the purely fratricidal nature of the NK cells. They attacked only related leukemia cells, while unrelated breast cancer cells did not die off in large numbers when put into contact with the NK cells. The team is still unclear on why exactly the NK cells behave this way, but hypothesize that other, yet-to-be-discovered antibodies could be the key to turning other cancerous cell types into NK cells.
Lerner has named this type of therapy “fratricidins,” and pointed out that they would have several advantages. The antibodies would be clinically useful with little to no modification, and the high specificity of the NK cells would reduce the likelihood of damage to surrounding healthy cells. This would make fratricidins a possible treatment with much more tolerable effects than traditional treatments like chemotherapy.
On top of that, every cancer cell in a population is potentially convertible, so in a successful therapy the cancer-cell population might not just be reduced, but eliminated entirely.
Read more: Cancer Treatment Breakthrough: Researchers Engineer A Way To Make Leukemia Cells Kill Each Other
The Latest on: Cancer Treatment Breakthrough
[google_news title=”” keyword=”Cancer Treatment Breakthrough” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer Treatment Breakthrough
- New breakthrough treatment available for nonmelanoma skin canceron April 17, 2024 at 6:57 pm
A breakthrough treatment for nonmelanoma skin cancer now available in Western Washington has over a 99 percent cure rate.
- Dr. Marc Siegel: This is a 'groundbreaking' approach to treating children with canceron April 17, 2024 at 12:17 pm
Fox News medical contributor Dr. Marc Siegel breaks down a new breakthrough treatment for childhood cancer and comments on a CDC investigation into botched Botox.
- Nanoparticle delivery of FZD4 to lung endothelial cells inhibits lung cancer progression and metastaseson April 16, 2024 at 8:18 pm
A recent breakthrough study has shown potential to improve therapeutic outcomes for patients suffering from lung cancers.
- Australian researchers make breakthrough with targeted liver cancer treatmenton April 15, 2024 at 6:19 pm
Souha Youssef, a co-author of the study from the Center for Pharmaceutical Innovation at UniSA, said that the films could revolutionize liver cancer treatments by bridging the gap for patients who ...
- Breakthrough Prostate Cancer Research Aims to Halt Disease Progressionon April 15, 2024 at 5:12 am
Scientists at the University of Nottingham have discovered that prostate cancer is able to spread through a man’s body by taking off the genetic ‘handbrake’ that stops cells growing out of control — a ...
- Symptoms to know amid cancer breakthrough as new drug 'attacks' pancreatic tumours - shrinking 70% of themon April 15, 2024 at 12:04 am
A new experimental drug has shown promising results in the fight against cancer, shrinking up to 70% of pancreatic tumours. This significant breakthrough in cancer treatment was revealed in a recent ...
- French-Canadian gets 'Oscars of Science' prize for cancer treatmenton April 14, 2024 at 1:09 am
French-Canadian scientist Michel Sadelain was awarded an "Oscars of Science" prize in Los Angeles on Saturday for his research into genetically modifying immune cells to fight cancer.Around 20 other ...
- Father fights to find cure for his son’s canceron April 11, 2024 at 5:48 pm
Father Fernando Goldsztein has raised millions to find a cure for a rare brain tumor his son was diagnosed with at age nine called Medulloblastoma.
- Van Andel Institute scientists make breakthrough in colorectal cancer treatmenton April 11, 2024 at 11:36 am
GRAND RAPIDS, Michigan — Scientists at Van Andel Institute have made a breakthrough discovery in cancer treatment —specifically colorectal cancer. In March, research found pairing two separate ...
- FIU unveils breakthrough cancer treatment plans for pediatric patientson April 10, 2024 at 5:00 pm
(WSVN) - Researchers from Florida International University have created a new method that promises to personalize cancer treatments ... a better idea of which treatment path could be more ...
via Bing News